The landscape of medical radiotherapeutics is rapidly evolving, showcasing a multitude of innovative treatments that target specific cancers and related symptoms with unprecedented precision. Utilising various radionuclides, these therapies represent a new frontier in the fight against cancer, offering hope for more effective and personalised treatment options.
Central to this advancement is the use of Actinium-225 (Ac-225), an alpha-emitting radionuclide, in a range of promising therapies. Alpha particles, with their high energy and short range, are effective in destroying cancer cells while minimising collateral damage to surrounding healthy tissues.
For instance, Ac-225-DOTA-SP targets Substance P receptors in glioblastoma, a notably aggressive brain tumour, delivering alpha radiation directly to the tumour site. This targeted approach is echoed in Ac-225-DOTA-YS5 and Ac-225-FPI-2265, both aimed at treating prostate cancer through different mechanisms. Ac-225-DOTA-YS5 targets CD46 using monoclonal antibody IgG1, whereas Ac-225-FPI-2265 focuses on the Prostate-Specific Membrane Antigen (PSMA) with PSMA-I&T.
The targeting of neuroendocrine tumours (NETs) has also seen significant developments with agents like Ac-225-DOTATOC and Ac-225-RYZ101, which focus on somatostatin receptors, delivering alpha radiation precisely to tumour cells. Further, Ac-225-DOTAZOL for bone pain palliation in patients with bone metastases exemplifies the versatility of radiotherapeutics, directly targeting bone tissues to provide pain relief.
Beyond alpha emitters, beta-emitting radionuclides like Yttrium-90 (Y-90) and Lutetium-177 (Lu-177) are also making strides in radiotherapeutics. Y-90 is employed in treating hepatocellular carcinoma and non-Hodgkin’s lymphoma, while Lu-177 is used in therapies for prostate cancer and neuroendocrine tumours.
Expanding the repertoire, treatments like At-211-81C6 mAb (Neuradiab) target brain cancer by using Astatine-211, another alpha emitter, conjugated with the monoclonal antibody 81C6. Similarly, At-211-MABG, targeting adrenergic tissues, is being developed for conditions like paragangliomas and pheochromocytoma.
Furthermore, Radium-223 (Ra-223) in Radium Dichloride therapy stands out for its application in bone pain palliation, particularly for metastatic prostate cancer. This therapy mimics calcium and selectively targets bone metastases, delivering alpha radiation.
The field also sees the development of therapies like Iodine-131 (I-131) in various forms, such as I-131-Apamistamab (Iomab-B™) for acute lymphoblastic leukaemia and Hodgkin’s lymphoma and I-131-Metuximab for hepatocarcinoma. Each of these I-131-based therapies leverages the beta radiation emitted by I-131 to target specific cancer cells.
In conclusion, the diversity of radiotherapeutics, from alpha and beta emitters to different targeting mechanisms, underscores the remarkable progress in this field. These therapies are advancing and redefining cancer treatment, offering more precise, effective, and patient-tailored options. As research and clinical trials continue, these groundbreaking developments in radiotherapeutics are poised to significantly impact the future of cancer therapy.
You are here:
home »
By | 4 minutes of readingLutetium-177 PSMA-R2 is a urea-based therapeutic agent targeting PSMA, effectively treating advanced prostate cancer patients.
The Development of Lutetium-177 PSMA-R2: A Novel Therapeutic Agent for Prostate Cancer Read Post »
By | 4 minutes of readingLutetium-177 PSMA-ALB-56 is an innovative treatment optimising prostate cancer therapy through targeted radiopharmaceutical advancements.
Lutetium-177 PSMA-ALB-56: A Promising Radiopharmaceutical for Prostate Cancer Therapy Read Post »
By | 4 minutes of readingLutetium-177 PNT6555, a FAP-targeted radiopharmaceutical, combines precision therapy with beta radiation for tumour-specific treatment.
Lutetium-177 PNT6555: A Breakthrough in FAP-Targeted Radiopharmaceutical Therapy Read Post »
By | 4 minutes of readingLutetium-177 PNT2002 offers targeted radiotherapy for prostate cancer, combining precise tumour targeting with therapeutic and diagnostic capabilities.
Lutetium-177 PNT2002: A Promising PSMA-Targeted Radiopharmaceutical Read Post »
By | 4 minutes of readingLutetium-177 Pentixather targets CXCR4-expressing tumours, delivering precise beta radiation therapy to eliminate malignant cells effectively.
By | 15 minutes of readingLutetium-177 Oxodotreotide Treatment offers targeted neuroendocrine tumour therapy, improving progression-free survival and patient outcomes significantly.
Neuroendocrine Tumour Therapy with Cutting-Edge Lutetium-177 Oxodotreotide Innovation Read Post »
By | 10 minutes of readingLutetium-177 MVT-1075 radioimmunotherapy targets pancreatic cancer by utilising CA19-9 specificity, sialyl-Lewis a binding, and precision radiation delivery.
Lutetium-177 MVT-1075: A Breakthrough in Pancreatic Cancer Radioimmunotherapy Read Post »
By | 10 minutes of readingLutetium-177 Ludotadipep targets PSMA with enhanced stability, specificity, and reduced side-effects, revolutionising prostate cancer treatment.
By | 10 minutes of readingLutetium-177 LNC1010, a radiolabelled therapy, targets somatostatin receptors, delivering precise treatment with minimal side effects.
By | 4 minutes of readingA novel radiolabelled drug, Lutetium-177 LNC1004, targets fibroblast activation protein, transforming cancer therapy through precision and innovation.
By | 4 minutes of readingBetalutin combines the precision of CD37-targeting antibody Lilotomab with Lutetium-177, offering targeted and effective haematological cancer treatment.
Betalutin: A Revolutionary Therapeutic Pathway in Haematological Cancer Treatment Read Post »
By | 4 minutes of readingTargeting glioblastoma with Lutetium-177 ITM-31 offers precise intracavitary treatment, reducing recurrence by specifically addressing residual cancer cells post-surgery.
Targeting Glioblastoma with Precision: The Promise of Lutetium-177 ITM-31 Read Post »
By | 5 minutes of readingLutetium-177 iPSMA revolutionises prostate cancer treatment, delivering targeted beta radiation to metastatic cells with precision and minimal side effects.
Lutetium-177 iPSMA: A Game-Changer in Prostate Cancer Therapy Read Post »
By | 5 minutes of readingTargeting Neurotensin Receptor-1 with Lutetium-177 IPN-01087 demonstrates promising precision therapy, delivering beta radiation for treating invasive cancers like ductal pancreatic adenocarcinoma.
Targeting Neurotensin Receptor-1: Lutetium-177 IPN-01087 in Oncology Read Post »
By | 4 minutes of readingAdvancing prostate cancer treatment, Lutetium-177 HTK03170 and Gallium-68 HTK03149 enable targeted PSMA therapy, improving diagnosis and therapeutic outcomes.
By | 4 minutes of readingLutetium-177 FAPI-04 revolutionises cancer treatment by precisely targeting cancer-associated fibroblasts, enabling dual imaging and radiotherapy functionalities for enhanced outcomes.
Innovative Radiotherapeutics: Lutetium-177 FAPI-04 as a Game-Changer in Cancer Treatment Read Post »
By | 4 minutes of readingRevolutionising cancer therapy, Lutetium-177 FAP-2286 offers precise diagnostics and targeted treatment, addressing solid tumours and fibrotic conditions effectively.
By | 5 minutes of readingLutetium-177 EDTMP provides a cost-effective, accessible, and efficacious alternative for bone pain palliation in metastatic cancer patients.
Lutetium-177 EDTMP: A Cost-Effective Alternative for Bone Pain Palliation in Cancer Read Post »
By | 9 minutes of readingLutetium-177 Edotreotide revolutionises neuroendocrine tumour treatment through targeted radioligand therapy, enhancing precision and improving patient outcomes.
By | 10 minutes of readingLutetium-177 EB-PSMA-617 represents an innovative radioligand therapy optimising tumour retention and therapeutic outcomes in metastatic prostate cancer.
By | 10 minutes of readingLutetium-177 DTPA-Omburtamab offers hope in neuroblastoma treatment by precisely targeting B7-H3, delivering localised radiation while sparing healthy tissues.
By | 9 minutes of readingLutetium-177 DPI-4452 pioneers precision radiotheranostics, revolutionising treatment for CAIX-expressing solid tumours through targeted imaging, therapy, and personalised oncology care advancements.
By | 10 minutes of readingLutetium-177 DOTAZOL offers a dual-function approach, combining targeted radiotherapy and bone modulation, enhancing treatment for prostate cancer-related bone metastases.
By | 9 minutes of readingLutetium-177 DOTA-EB-TATE enhances neuroendocrine tumour therapy by improving tumour uptake, retention, and pharmacokinetics through albumin-binding Evans blue moieties.
Neuroendocrine Tumour Therapy: The Rise of Lutetium-177 DOTA-EB-TATE Read Post »
By | 10 minutes of readingLutetium-177 DOTA-EB-FAPi revolutionises oncology by enhancing precision targeting of fibroblast activation protein, improving tumour uptake, and expanding therapeutic applications.
Lutetium-177 DOTA-EB-FAPi: Pioneering a New Era in Precision Oncology and Beyond Read Post »
By | 4 minutes of readingLutetium-177 Debio 1124, a second-generation theranostic agent, selectively targets CCK2R-expressing tumours, offering precision radiotherapy and personalised oncology advancements.
By | 4 minutes of readingLutetium-177 CTT1403, an innovative PSMA-targeted therapy with irreversible phosphoramidate-based binding, shows remarkable efficacy in treating metastatic prostate cancer, enhancing tumour uptake, internalisation, and therapeutic precision.
Lutetium-177 CTT1403: A Therapeutic Breakthrough in Prostate Cancer Treatment Read Post »
By | 4 minutes of readingExploring Lutetium-177 AMTG highlights its innovative design, enhanced metabolic stability, and potential for effectively treating GRPR-positive prostate and breast tumours.
By | 5 minutes of readingIodine-131 Weimeisheng revolutionises advanced lung cancer treatment by combining targeted monoclonal antibody precision with beta radiation for improved outcomes.
Iodine-131 Weimeisheng: Transforming Advanced Lung Cancer Treatment Read Post »
By | 4 minutes of readingThe rise and fall of Iodine-131 Tositumomab highlights challenges in balancing innovation, efficacy, infrastructure, and cost within radiopharmaceutical therapies.
The Rise and Fall of Iodine-131 Tositumomab: Bexxar’s Story Read Post »
By | 4 minutes of readingIodine-131 TM601, a synthetic radiolabelled peptide, targets tumour cells expressing Annexin A2, delivering therapeutic radiation and exhibiting anti-angiogenic properties effectively.
Iodine-131 TM601: Targeting Tumours with Radiolabelled Peptides Read Post »
By | 5 minutes of readingPeptide Receptor Radionuclide Therapy utilises radiopharmaceuticals to target somatostatin receptor-expressing tumours, improving treatment outcomes significantly.
By | 4 minutes of readingTLX101 is a revolutionary radiopharmaceutical targeting gliomas, offering dual imaging and therapy through tumour-selective uptake, enhancing treatment outcomes.
TLX101: A Pioneering Radiopharmaceutical for Glioma Diagnosis and Therapy Read Post »
By | 4 minutes of readingIodine-131 Sodium Iodide plays a pivotal role in diagnosing and treating thyroid diseases, including carcinomas, through targeted radiotherapy and imaging.
The Role of Iodine-131 Sodium Iodide in Thyroid Disease Diagnosis and Therapy Read Post »
By | 5 minutes of readingIodine-131 RPS-001, a radiolabelled small molecule targeting PSMA, shows promise in prostate cancer therapy through precision-directed beta radiation delivery.
Iodine-131 RPS-001: A Promising Radiolabelled Molecule in Prostate Cancer Therapy Read Post »
By | 4 minutes of readingIodine-131 Omburtamab offers targeted radiation therapy, significantly improving survival in neuroblastoma patients with CNS and leptomeningeal metastasis.
Iodine-131 Omburtamab: A Breakthrough in Neuroblastoma Therapy Read Post »
By | 6 minutes of readingIodine-131 naxitamab (¹³¹I-3F8) targets GD2-expressing cancers, offering precise radioimmunotherapy for neuroblastoma, melanoma, and small cell lung carcinoma.
The Role of Iodine-131 Naxitamab (¹³¹I-3F8) in Treating Neuroblastoma and Other Cancers Read Post »
By | 5 minutes of readingIodine-131 Metuximab (Licartin) selectively targets CD147 receptors, delivering beta radiation to hepatocellular carcinoma cells, improving treatment precision significantly.
Iodine-131 Metuximab (Licartin): A Radiolabelled Antibody for Hepatocarcinoma Treatment Read Post »
By | 4 minutes of readingIodine-131 Lipiodol has re-emerged as a promising therapy for hepatocellular carcinoma, particularly in non-resectable cases with portal vein thrombosis.
By | 4 minutes of readingIodine-131 Iopofosine selectively delivers cytotoxic radiation to malignant cells by targeting the PI3K/Akt pathway, offering promising cancer therapy advancements.
Iodine-131 Iopofosine: A Novel Radiolabelled Alkyl Phosphocholine for Cancer Therapy Read Post »
By | 8 minutes of readingIodine-131 Iobenguane revolutionises neuroendocrine tumour management by offering targeted imaging and therapy, significantly improving diagnosis, treatment, and patient outcomes.
By | 10 minutes of readingPeptide Receptor Radionuclide Therapy offers a targeted approach to treating neuroendocrine tumours, improving survival rates and quality of life.
Advances in Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours Read Post »
By | 9 minutes of readingThis article reviews key Phase III clinical trials for ALSYMPCA, NETTER-1, and VISION therapies, highlighting advancements in cancer treatment.
Clinical Trials: Advancements in ALSYMPCA, NETTER-1, and VISION Therapies Read Post »
By | 9 minutes of readingTargeted Radionuclide Therapy for cancer delivers radioactive isotopes directly to tumour cells, maximising therapeutic effectiveness.
Biological Principles of Targeted Radionuclide Therapy for Cancer Read Post »
By | 3 minutes of readingIodine-131 IMAZA innovatively binds to adrenal cortex enzymes, revolutionizing the treatment and imaging of adrenocortical carcinoma effectively.
By | 3 minutes of readingIodine-131 ICF01012, targeting melanin receptors, shows promise in the fight against metastasised melanomas, heralding a new era in treatment.
By | 3 minutes of readingIodine-131 chTNT, aiming to revolutionise oncology, shows promise in targeting and eradicating tumour cells with precision.
Exploring Iodine-131 chTNT: A Beacon of Hope in Cancer Treatment Read Post »
By | 3 minutes of readingIodine-131 CAM-H2 heralds a new era in oncology, offering hope through precise targeting of HER2-expressing cancers with minimal side effects.
Exploring Iodine-131 CAM-H2 for Treating HER2-Expressing Cancers Read Post »
By | 3 minutes of readingIodine-131 BA52, a melanin-binding therapeutic, offers new hope for patients with melanin-positive malignant melanomas.
Exploring Iodine-131 BA52: A Novel Melanin-Targeted Therapy for Malignant Melanomas Read Post »
By | 3 minutes of readingTargeting Blood Cancers: The Role of Iodine-131 Apamistamab in Revolutionising Treatment for AML and Beyond.
The Role of Iodine-131 Apamistamab for Acute Myeloid Leukaemia Read Post »
By | 3 minutes of readingIodine-131 Monoclonal Antibody 81C6 specifically targets glioma cells by honing in on the tenascin protein.
Iodine-131 Monoclonal Antibody 81C6 Targets Glioma Cells Read Post »
By | 3 minutes of readingHolmium-166 Phytate, initially developed for chronic synovitis, has shown significant promise in phase I/II clinical trials.
Holmium-166 Phytate Offers a Promising Treatment Option for Chronic Synovitis Read Post »
By | 3 minutes of readingHolmium-166 Chitosan, a groundbreaking radiopharmaceutical, offers new hope in treating hepatocellular carcinoma with targeted therapy.
Holmium-166 Chitosan in Radiopharmaceutical Cancer Treatment Read Post »
By | 3 minutes of readingHolmium-166 microspheres, by delivering localized radiation, significantly enhance the therapeutic approach to inoperable liver cancer treatment.
The Role and Impact of Holmium-166 Microspheres in Brachytherapy Read Post »
By | 3 minutes of readingThe innovative 169Er-Erbium Citrate therapy precisely targets small joints, significantly easing arthritis with minimal side effects.
Erbium-169 Citrate: A Revolution in Small Joint Arthritis Treatment Read Post »
By | 3 minutes of readingCopper-67 SARTATE emerges as a groundbreaking radiopharmaceutical in targeted cancer therapy, showcasing promising clinical trial results.
Unlocking the Potential of Copper-67 SARTATE in Targeted Radiopharmaceutical Therapy Read Post »
By | 3 minutes of readingCopper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment Read Post »
By | 3 minutes of readingCopper-64 Diasparagine offers a promising breakthrough in targeting and treating aggressive brain tumours like glioblastoma.
By | 3 minutes of reading213Bi-Lintuzumab demonstrated efficacy in AML treatment, offering a targeted approach with manageable side effects, yet development paused.
Bismuth-213 Lintuzumab: A Promising Treatment for Acute Myeloid Leukaemia Read Post »
By | 3 minutes of reading213Bi-DOTATOC offers potent, targeted alpha therapy for tumours, advancing treatment with precision and reduced systemic toxicity.
Bismuth-213 DOTATOC: A Promising Alpha-Labelled Analogue for Tumour Therapy Read Post »
By | 3 minutes of reading211At-Parthanatine, targeting PARP1 with alpha radiation, promises precise cancer therapy, especially for high-risk neuroblastomas.
By | 3 minutes of readingAstatine-211 Sodium Astatide, evolving thyroid treatment, enters trials, promising enhanced precision and safety over traditional Iodine-131 NaI therapy.
Astatine-211 Sodium Astatide: The Next Generation in Thyroid Disease Treatment Read Post »
By | 3 minutes of reading211At-MX35-F(ab’)2 shows promise in treating ovarian cancer through targeted therapy in ongoing clinical trials.
The Potential of Astatine-211-MX35-F(ab’)2 in Ovarian Cancer Treatment Read Post »
By | 3 minutes of readingThe innovative 211At-MABG targets rare tumours like malignant pheochromocytoma and paragangliomas, promising a new era in treatment.
Astatine-211 MABG in Malignant Pheochromocytoma and Paragangliomas Read Post »
By | 17 minutes of readingTherapeutic nuclear medicine leverages radionuclides for targeted cancer treatment, facing challenges in delivery, safety, and regulatory compliance.
By | 3 minutes of reading211At-BC8-B10, targeting CD45 in leukemia, combines BC8 antibody with Astatine-211, showing promising clinical trials.
Astatine-211 BC8-B10: A Promising Radioimmunoconjugate for Leukaemia Treatment Read Post »
By | 3 minutes of readingAstatine-211 in radiotheranostics offers targeted, effective cancer treatment, but faces production and safety challenges.
Astatine-211 Radiotheranostics: A New Era in Cancer Treatment Read Post »
By | 3 minutes of reading211At-81C6-mAb, targeting tenascin in brain tumours, shows extended survival but needs further funding for development.
Astatine-211 81C6-mAb: A Breakthrough in Brain Tumour Treatment with Alpha Radiation Read Post »
By | 3 minutes of reading225Ac-RYZ101 offers promising GEP-NET treatment, targeting tumours with alpha particles via somatostatin receptor-specific edotreotate.
By | 4 minutes of reading225Ac-Rosopatamab, targeting metastatic prostate cancer, combines monoclonal antibodies with alpha radiation, showing promise in early trials.
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment Read Post »
By | 4 minutes of reading225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Post »
By | 3 minutes of reading225Ac-MTI-201, targeting MC1R, offers groundbreaking, targeted treatment for uveal melanoma with minimal side effects.
Actinium-225 MTI-201: A Promising New Agent in Uveal Melanoma Treatment Read Post »
By | 3 minutes of reading225Ac-Lintuzumab, targeting CD33, shows promise in AML treatment with potential expansion to other cancers.
Actinium-225 Lintuzumab: A Breakthrough in Acute Myeloid Leukaemia Treatment Read Post »
By | 3 minutes of readingActinium-225 is a rare, promising isotope revolutionizing targeted alpha therapy for various resistant cancers.
Actinium-225: The Emerging Star in Targeted Alpha Therapy Read Post »
By | 3 minutes of reading225Ac-FPI-2265, targeting PSMA, shows promise in treating advanced prostate cancer in the TATCIST clinical trial.
By | 4 minutes of reading225Ac-FPI-2068 and 111In-FPI-2107 represent a major advancement in targeted alpha therapy for various solid tumours.
By | 4 minutes of reading225Ac-FPI-2059 targets NTSR1 in cancer cells, offering a novel approach in pancreatic cancer treatment.
Actinium-225 FPI-2059: Targeted Alpha Therapy in Oncology through NTSR1 Targeting Read Post »
By | 4 minutes of reading225Ac-FPI-1434 advances in clinical trials, targeting IGF-1R in chemo-resistant solid tumors with promising results.
By | 3 minutes of reading225Ac-DOTAZOL enhances 177Lu-radiotherapy in bone diseases, particularly effective in prostate cancer, as shown in preclinical studies.
By | 5 minutes of reading225Ac-DOTATOC advances GEP-NET treatment, offering targeted, effective therapy for patients resistant to traditional methods.
By | 5 minutes of reading225Ac-DOTA-YS5 targets CD46 in prostate cancer, promising precision and effectiveness in therapy.
By | 4 minutes of reading225Ac-DOTA-SP, a breakthrough in targeted alpha therapy, offers precise cancer treatment with minimal side effects, revolutionising oncological approaches.
